MoonLake Immunotherapeutics Overview
MoonLake Immunotherapeutics Target Price
Analysts' 12-month price predictions for MLTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$19.52
Average Target Price
$45.00
130.5% upside
130.5% upside1 analysts in the last 4 months
High: $45 | Low: $45
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-11 | H.C. Wainwright | $45 | 130.5% upside |  |
| 2026-02-24 | Oppenheimer | $35 | 79.3% upside | |
| 2026-01-14 | Goldman Sachs | $10 |  48.8% downside | |
| 2026-01-09 | H.C. Wainwright | $32 | 63.9% upside | |
| 2026-01-09 | UBS | $24 | 23% upside | |
| 2026-01-08 | UBS | $45 | 130.5% upside | |
| 2025-11-21 | H.C. Wainwright | $26 | 33.2% upside | |
| 2025-11-06 | Oppenheimer | $30 | 53.7% upside | |
| 2025-11-03 | H.C. WainwrightRaghuram Selvaraju | $30 | 53.7% upside | |
| 2025-10-07 | Oppenheimer | $25 | 28.1% upside | |
| 2025-09-30 | Goldman Sachs | $7 | 64.1% downside | |
| 2025-09-30 | NeedhamSerge Belanger | $20 | 2.5% upside | |
| 2025-09-30 | Guggenheim | $20 | 2.5% upside | |
| 2025-09-29 | Jefferies | $8 | 59% downside | |
| 2025-09-29 | RBC Capital | $10 | 48.8% downside | |
| 2025-03-18 | RBC Capital | $67 | 243.2% upside | |
| 2024-07-01 | H.C. WainwrightRaghuram Selvaraju | $100 | 412.3% upside | |
| 2024-04-02 | Goldman SachsRichard Law | $62 | 217.6% upside | |
| 2023-08-31 | NeedhamSerge Belanger | $76 | 289.3% upside | |